CD33 CAR Immune Cells for Relapsed AML Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML), particularly in elderly patients, are limited, with poor response rates and high mortality, and there is a need for novel therapies with a favorable safety profile that can target leukemic stem cells to prevent relapse.
Innovation Solution
Development of chimeric antigen receptors (CARs) comprising a CD33 antigen binding domain, stalk domain, transmembrane domain, costimulatory signaling domains like 4-1BB or CD28, and CD3 zeta signaling domain, engineered into immune effector cells to stimulate a T-cell mediated immune response against AML cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard induction chemotherapy is administered to elderly AML patients, then some leukemic cells are killed, but treatment-related mortality is high and complete response rates are low
Solution Approach 1:
The patent uses chimeric antigen receptors (CARs) as intermediary molecules that enable T cells to recognize and attack AML cells expressing CD33 or CD123 antigens. This intermediary mechanism allows targeted killing of leukemic cells without requiring the elderly patients to tolerate intensive conventional chemotherapy, thereby improving treatment efficacy while reducing treatment-related mortality
Solution Approach 2:
The patent replaces the mechanical/chemical system of conventional chemotherapy with a biological immune system approach. Instead of using cytotoxic drugs that non-specifically damage dividing cells, the invention employs genetically modified T cells that specifically recognize and eliminate AML cells through antigen-specific recognition, reducing off-target toxicity and treatment-related mortality
2Productivity
If conventional chemotherapy is used to treat AML, then some cancer cells are eliminated, but leukemic stem cells are not effectively targeted leading to relapse
Solution Approach 1:
The patent applies local quality by engineering different CAR specificities to target different antigen profiles. Some T cells are modified to recognize CD33 while others target CD123, allowing the immune response to focus on specific leukemic cell populations including stem cells that express these antigens, thereby preventing relapse while maintaining high cancer cell elimination rates
Solution Approach 2:
The patent employs dynamic adaptation by using multiple CAR specificities that can respond to heterogeneous AML populations. The dual-targeting approach (CD33 and CD123) allows the immune system to dynamically adapt to different antigen expressions on leukemic cells, ensuring comprehensive elimination including resistant stem cell populations
3Adaptability or versatility
If novel CAR-T cell therapy is developed to target AML, then treatment options are expanded and efficacy is improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent segments the CAR structure into distinct functional domains: an extracellular antigen-binding domain (single-chain variable fragment), a transmembrane domain, and intracellular signaling domains (CD3 zeta chain and costimulatory domains like 4-1BB or CD28). This segmentation allows modular design and construction of CARs with different specificities while maintaining a consistent structural framework, thereby expanding treatment options without proportionally increasing complexity
Solution Approach 2:
The patent employs universal structural elements across different CAR designs, including standardized transmembrane domains and signaling domains that can be combined with different antigen-binding specificities. This multi-functionality allows the same basic CAR architecture to target multiple antigens (CD33, CD123), expanding treatment versatility while using proven, well-characterized structural components
Data Source
AI summary
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.